Economic contribution of prophylactic immunosuppressive therapy with mycophenolate mofetil in renal cadaveric transplant recipients;Apport economique du mycophenolate mofetil comme traitement immunosuppresseur prophylactique apres transplantation renale de cadavre

Presse Medicale

Volumn 25, Issue 33, 1996, Pages 1577-1582

  Loiris Toitizer, C ^a   Nuijten, M J C ^b   Boyle, F ^a   Cantarovich, D ^b   Lang, P ^c   Lebranchu, Y ^d   Le Pogamp, P ^e   Touraine, J L ^f   Vialtel, P ^a   Monroe, T ^g   De Vries, M J ^h  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Institut de Transplantation et de Recherche en Transplantation Dieu   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d CHU BRETONNEAU   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g CH Basel   (United States)

^h Produits Roche ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PLACEBO;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH ECONOMICS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; ADULT; AMBULATORY CARE; CADAVER; COST; ECONOMICS; GRAFT REJECTION; HOSPITALIZATION; POSTOPERATIVE COMPLICATION; TIME;

ADULT; AMBULATORY CARE; AZATHIOPRINE; CADAVER; COSTS AND COST ANALYSIS; GRAFT REJECTION; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PLACEBOS; POSTOPERATIVE COMPLICATIONS; TIME FACTORS;

EID: 10344258539     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bonan H, Du Mesnil du Buisson, M-A. Enquête sur la dialyse rénale, Rapport présenté par : H Bonan et M-A du Mesnil du Buisson, Membres de l'Inspection générale des affaires sociales, Code mission SA/AC/AP 940041, Rapport nr. 94.092, Septembre 1994.
2. Schneider T, Fagnani F, Lanoe, JL Hourmant, M, Soulilou, JP. Economie analysis of an immunosuppressive strategy in renal transplantation. Health Policy 1988 ; 9:75-89.
3. Russell, JD, Beecroft M., Ludwin D, Churchill DM. The quality of life in renal transplantation: A prospective study. Transplantation 1992 ; 54:656-60.
4. Evans RW, Manninen DL, Garrison LP et al. The quality of life of patients with end-stage renal disease. N EngtJ Med 1985; 312:553-9.
5. Conseil médical et scientifique de l'Etablissement français des Greffes. Activités de transplantation. In : Rapport annuel : le prélèvement et la greffe en France en 1994, EFG , Paris, 1994, 27-69.
6. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NU. The impact of renal rejection episodes on long-term graft function and outcome in 1347 primary renal transplantation patients treated by 3 cyclosporin regimes. Transplantation 1993; 56:307-15.
7. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky Ph. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992; 53:323-8.
8. Tesi RJ, Henry ML Elkhammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant 1993 ; 7:345-52.
9. Basadonna GP, Matas AJ, Gillingham KJ et al. Early versus late acute renal allograft rejection : Impact on chronic rejection. Transplantation 1993 ; 5:993-5.
10. Ferguson R. Acute rejection episodes: Best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8:328-31.
11. Morelon E, Thervet E, Legendre C. L'immunosuppression en transplantation rénale: réalités et perspectives. Méd Thér 1996, 2:227-34.
12. European Mycophenolate Mofetil Cooperative Study group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 ; 345:1321-5.
13. Sollinger HYV for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-32.
14. The Tricontinental Mycophenolate Mofetil Renal Transplant Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61:1029-37.
15. Clemens K. Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconnmics 1995; 8:169-74.
16. e.
17. Suthanthiran M, Strom TB. Medical progress: Renal transplantation. N EngI J Ued 1994 ; 331:365-76.
18. Burke AB, Chavers BM, Gillinghman KJ el al. Chronic renal allografl rejection in the first 6 months posttransplant. Transplantation 1995 ; 60:1413-17.